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Warfarin is the most commonly used anticoagulant worldwide. The 
effectiveness of warfarin therapy in reducing morbidity and mortality 
related to thromboembolic disease is well established.[1] The degree of 
anticoagulation effected by warfarin is determined by measuring the 
prothrombin time and is reported as the international normalised 
ratio (INR).[1] The INR is influenced by a variety of factors that 
contribute to the complexity of warfarin therapy.[1] Warfarin has a 
narrow therapeutic index; in order to maximise the benefit from 
warfarin therapy while avoiding the risk of bleeding, the INR needs 
to be maintained within a target range for a period above a minimum 
amount of time.[2,3] This is known as the time in therapeutic range 
(TTR). A minimum TTR of 65% is required for warfarin therapy 
to be regarded as effective. Below this value, warfarin is unlikely to 
prevent thromboembolic disease effectively, and the risk of bleeding 
complications increases.[4,5] The TTR is a useful, albeit imperfect, 
parameter by which the quality of anticoagulation is estimated.[6]
Warfarin is the only readily available oral anticoagulant in the 
public health sector in South Africa (SA). There is a paucity of data 
regarding the quality of INR control, as well as the complications 
associated with poor INR control, in non-metropolitan and rural SA 
settings. Previous studies conducted in metropolitan areas in SA and 
in the wider sub-Saharan Africa region have shown INR control to be 
poor.[4,7-14] The quality of INR control in non-metropolitan and rural 
primary healthcare clinic (PHC) settings in SA is largely unknown. 
This lack of data is particularly important in light of the relative 
scarcity of resources and facilities and limited ability to manage 
complications related to poor INR control such as bleeding, stroke, 
peripheral emboli and valve thromboses in these settings.
The Garden Route District Municipality is situated in the south-
eastern part of Western Cape Province, SA. There are no dedicated 
anticoagulation clinics in the district, and patients requiring 
anticoagulation therapy are referred to their nearest PHC for initiation 
and/or continuation of warfarin therapy. INR testing is offered 24 hours 
a day at George Regional Hospital by the National Health Laboratory 
Service (NHLS). There are no standardised manual or computer-based 
algorithms regulating dosage adjustments or follow-up. Point-of-care 
(PoC) testing and self-testing are not currently available in the district. 
Samples are transported daily from distant PHC facilities and satellite 
clinics to George Regional Hospital for analysis, with some clinics 
>90 km away from the laboratory. The resultant delay in processing of 
samples often leads to delayed adjustment of warfarin dosage, as well 
as questionable results in some instances. Patients are often required to 
return to their local clinics on another day to obtain their results and 
have adjustments made to their therapy.
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Background. The quality of international normalised ratio (INR) control determines the effectiveness and safety of warfarin therapy. Data 
on INR control in non-metropolitan settings of South Africa (SA) are sparse.
Objectives. To examine the time in therapeutic range (TTR) and its potential predictors in a sample of Garden Route District Municipality 
primary healthcare clinics (PHCs).
Methods. INR records from eight PHCs were reviewed. The TTR and percentage of patients with a TTR >65% were determined. A host of 
variables were analysed for association with TTR.
Results. The median (interquartile range (IQR)) age of the cohort (N=191) was 56 (44 - 69) years. The median (IQR) TTR was 37.2% (20.2 - 
58.8); only 17.8% of patients had a TTR ≥65%. Compared with patients aged >50 years, those aged <50 had worse INR control (median 
(IQR) TTR 26.6% (16.1 - 53.0) v. 43.5% (23.5 - 60.1); p=0.01). Patients hospitalised for any reason during the study period had worse INR 
control than patients not hospitalised (median (IQR) TTR 26.2% (16.2 - 50.2) v. 42.9% (23.5 - 62.0); p=0.02). On multivariable regression 
analysis, participants on warfarin for atrial fibrillation/flutter had better INR control than those with other indications for warfarin (odds 
ratio 2.21; 95% confidence interval 1.02 - 4.77; p=0.04), but the control was still very poor.
Conclusions. INR control, as determined by TTR and proportion of TTR ≥65%, in these non-metropolitan clinics was poor. Age and 
hospitalisation as a marker of illness predicted poor control. There was a difference in control between groups, depending on the indication 
for warfarin. Evidence-based measures to improve the quality of INR control in patients on warfarin therapy need to be instituted as a 
matter of urgency.
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Objectives
To examine the quality of INR control in PHC clinics in a non-
metropolitan/rural setting in SA and assess the relationship between 
INR control and specific demographic and clinical factors over a 
12-month period. The specific objectives were to calculate the TTR 
and the proportion of patients with a TTR ≥65%; to analyse INR 
control stratified by age (≥50 years), gender, employment status, 
government support grant status and indication for warfarin; and to 
determine the influence of all-cause hospital admissions during the 
study period on INR control. Furthermore, the association between 
TTR and the frequency of INR testing and early follow-up of out-of-
range results with repeat testing was assessed. No outcomes of INR 
control were assessed in this study.
Methods
Study design
The study was a retrospective review of the records and available 
results of patients who underwent INR testing for the purpose of 
monitoring warfarin therapy at PHCs in the Garden Route District 
Municipality between July 2016 and June 2017.
Participating clinics
In order to represent different non-metropolitan and rural settings 
in the Garden Route District Municipality, eight PHCs were non-
randomly selected. Four clinics from small town centres, two clinics 
situated in townships and two rural satellite clinics were included.
Ethical considerations
Ethical approval for the study was granted by the University of 
Cape Town Human Research Ethics Committee (ref. no. 785/2017). 
Permission was obtained before data were made available from the 
NHLS. Permission for research and data collection in the PHCs was 
obtained from the Western Cape provincial government (ref. no. 
WC_201711_028).  As this was a retrospective review with no patient 
interaction, informed consent was not obtained.
Patient population
All patients aged ≥18 years who were on warfarin therapy and had 
INR testing performed during the study period were eligible. Those 
with an unknown indication for warfarin and/or <2 INRs performed 
during the study period were excluded.
Data collection
INR values were obtained from the NHLS database. Patient files 
were extracted at the relevant healthcare facilities to obtain the age, 
gender, employment status, indication for warfarin therapy, and 
whether the patient required hospital admission during the study 
period. The TTR was calculated using the Rosendaal method of 
linear interpolation, which assumes linear increases and decreases 
of the INR between successive INR values over time. From this 
assumption, the time period during which the INR falls within 
the predetermined therapeutic range can be calculated and can be 
converted to a percentage of total time.[6,15] For mechanical valve 
replacement an INR of 2.5 - 3.5 was regarded as therapeutic, and for 
all other indications a range of 2 - 3 was regarded as therapeutic.[16]
Statistical analysis
Statistical analysis was performed using Stata version 14.2 (StataCorp, 
USA). Descriptive statistics were used to summarise data. Continuous 
variables were summarised as means with standard deviations for 
parametric data or medians with interquartile ranges (IQRs) for non-
parametric data. Categorical variables were expressed as frequencies 
and percentages. Variables evaluated for association with INR control 
are shown in Table 1.
For age and TTR, categorical variables were created (age <50 years, 
TTR ≥65%). Continuous variables (i.e. TTR) were compared for age 
<50, gender and hospital admission during study period, using either 
Student’s t-test for parametric data or the Wilcoxon rank-sum test 
for non-parametric data. Categorical variables (i.e. TTR ≥65%) were 
compared for age <50, gender and hospital admission during the 
study period using χ2 and Fisher’s exact tests. Univariable regression 
analysis was performed using the following variables: age <50, gender, 
employment status, indication for anticoagulation therapy, and hospital 
admission during the study period. Variables significantly associated 
with a TTR ≥65% (p<0.05) were used for the multivariable regression 
model. A fit of the model was assessed using the Hosmer-Lemeshow 
goodness-of-fit test. The association between TTR and the number of 
INRs per patient, the time interval between tests and the percentage of 
out-of-range INRs that were followed up within 7 days with a repeat 
test was measured with a Spearman rank test. An r2 value approaching 
1 showed high levels of correlation between TTR and the number of 
INR tests, time interval between tests and percentage of out-of-range 




Of the 287 eligible participants, 191 met all the stipulated inclusion 
and exclusion criteria (Fig. 1). The median (IQR) age of the study 
population was 56 (44 - 69) years, and the majority of the partici-
pants (56.5%) were unemployed women on government support 
grants. In descending order, the three most common indications 




Employment status (employed, unemployed, government support grant)
Clinical variables
 Indication for warfarin therapy (atrial fibrillation/flutter, venous thromboembolism, mechanical prosthetic valve, antiphospholipid syndrome, 
left ventricular thrombus)
Hospital admission during study period for any indication
Total number of INR tests per patient 
Average time interval between tests (days)
Percentage of out-of-range INRs followed up within 7 days with repeat test
INR = international normalised ratio.
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for warfarin therapy were atrial fibrillation/
flutter (42.4%), venous thromboembolism 
(VTE) (28.8%) and mechanical prosthetic 
heart valves (24.1%) (Table 2).
Over the study period, a total of 2 635 INR 
tests were available for analysis. The median 
(IQR) TTR was 37.2% (20.2 - 58.8). Only 
17.8% of patients had a TTR ≥65%.
Table 3 outlines the TTR and percentage 
TTR ≥65% stratified by age (above and 
below 50 years), gender, employment status, 
grant status, indication for warfarin, and all-
cause hospital admission during the study 
period.
Regarding the TTR for different indi-
cations for warfarin, patients with atrial 
fibrillation and flutter had a median (IQR) 
TTR of 44.5% (25.3 - 62.3), patients with 
VTE a median of 26.7% (9.6 - 53.0), patients 
with a mechanical valve replacement a 
median of 38.3% (20.0 - 58.7), patients 
with antiphospholipid syndrome a median 
of 34.9 (6.3 - 50.1) and those with a left 
ventricular thrombus a median of 48.2% 
(11.5 - 71.7). Patients who were employed 
had a median (IQR) TTR of 28.8% (15.4  - 
51.9), unemployed patients a median of 
29.3% (16.2 - 59.1) and those receiving a 
government support grant a median of 46.8% 
(27.1 - 62.0). The results of the univariable 
and multivariable regression analysis for 
demographic and clinical factors associated 
with a TTR ≥65% are summarised in Table 4.
The multivariable regression analysis 
showed better INR control for patients with 
atrial fibrillation or flutter compared with 
other indications (odds ratio (OR) 2.21; 
95% confidence interval (CI) 1.02 - 4.77; 
p=0.04). Patients who were hospitalised 
during the study period had worse INR 
control than those who were not hospitalised 
(OR 0.39; 95% CI 0.15 - 0.98; p=0.05). 
However, this did not remain significant 
in the multivariable model (OR 0.39; 95% 
CI 0.15 - 1.03; p=0.06). As shown in Table 
5, no significant associations were found 
between TTR and total INR tests, INR 
testing frequency, or percentage of repeat 
testing for out-of-range values within 7 days.
Discussion
This is the first comprehensive study to 
assess the quality of INR control in a non-
metropolitan PHC setting in SA. There were 






• <2 INRs, n=40
• INRs at multiple clinics, n=13
• Not on warfarin, n=33
• Unknown indication for warfarin, n=10
Fig. 1. Study participants selection diagram. (INR = international normalised ratio.)
Table 2. Baseline characteristics of the study population (N=191)
Age (years), median (IQR) 56 (44 - 69)
Female, median (IQR) 108 (56.5)
Employment status, n (%)
Employed 32 (16.8)
Unemployed 59 (30.9)
Government support grant 60 (31.4)
Unknown employment status 40 (20.9)
Indication for warfarin, n (%)
Atrial flutter/fibrillation 81 (42.4)
Venous thromboembolism 55 (28.8)
Mechanical valve replacement 46 (24.1)
Antiphospholipid syndrome 6 (3.1)
Left ventricular thrombus 3 (1.6)
All-cause hospital admission during study period, n (%) 62 (32.5)
INR tests per patient, median (IQR) 13 (7 - 19)
Duration of INR testing (months), median (IQR) 10.1 (6.6 - 11.4)
Time interval between INR tests (days), median (IQR) 21.4 (14.3 - 31.6)
INR tests in range (%), median (IQR) 33.3 (16.7 - 47.4)
Out-of-range tests above range (%), median (IQR) 33.3 (14.8 - 50)
Out-of-range tests below range (%), median (IQR) 66.7 (50.0 - 85.2)
Out-of-range INRs followed up within 7 days with repeat INR (%), median (IQR) 22.2 (0 - 45.5)
TTR (%), median (IQR) 37.2 (20.2 - 58.8)
Percentage TTR ≥65%, n (%) 34 (17.8)
IQR = interquartile range; INR = international normalised ratio; TTR = time in therapeutic range.
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monitoring in the eight broadly representative PHCs included was 
poor, as evidenced by a median TTR of 37.2% and a TTR ≥65% 
of 17.8%. Second, we found that the only clinical, demographic or 
social predictors of poor INR control were age and the need for 
hospitalisation. Patients with atrial fibrillation/flutter had better 
INR control than those with other indications for warfarin, but the 
TTR was well below acceptable effective levels. There was lack of a 
significant association between TTR and all other variables included 
in our models.
We did not assess patient outcomes in the study. However, given 
the well-established relationships between poor INR control and 
major adverse events, the finding that 82.2% of our patients were 
unlikely to derive any significant benefit from warfarin therapy, and 
were at increased risk of developing thrombotic and thromboembolic 
(as well as haemorrhagic) complications, is concerning.
Our findings correlate with a limited number of previous studies 
in SA and confirm that INR control in the public health sector in SA, 
and particularly in rural settings, is poor.[7-9] Importantly, our findings 
suggest that compared with INR control in urban and peri-urban 
anticoagulation clinics, INR control outside these settings is worse. 
In the Cape Town metropolitan area, Barth et al.[7] demonstrated a 
mean TTR of 42% in patients with rheumatic heart disease without 
previous mitral valve replacement surgery, and 67% in patients who 
had had a previous mitral valve replacement. However, the study 
sample was small and only 334 INRs were analysed. Sonuga et al.[9] 
demonstrated, in a cross-section-of-files review at a secondary-level 
hospital INR clinic in Cape Town, that 48.5% of INRs were outside 
the target range. Only 136 INR values were included in the analysis. 
Ebrahim et al.[8] compared the TTR at two INR clinics in the Cape 
Town metropolitan area and calculated a mean TTR of 47%, with 
only 25.1% of patients having a TTR ≥65%.[8]
Data from large multicentre international trials also give some 
insight into the quality of INR control for atrial fibrillation in SA. 
Three large international multicentre trials, namely the Rivaroxaban 
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin 
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET AF), the Randomised Evaluation of Long-Term 
Anticoagulation Therapy trial (RE-LY), and the Clopidogrel Trial 
Table 3. Patient-related variables and TTR
TTR (%), median (IQR) p-value TTR ≥65%, n/N (%) p-value
Age (years)




≥50 43.5 (23.5 - 60.1) 25/120 (20.8)
Gender




Male 46.6 (20.7 – 63.0) 20/83 (21.1)
All-cause admission during study period




Not admitted 43.0 (23.5 – 62.0) 28/129 (21.7)
TTR = time in therapeutic range; IQR = interquartile range.
Table 4. Univariable and multivariable regression analysis of demographic and clinical factors associated with a TTR ≥65%*
Variables
           Univariable regression analysis   Multivariable regression analysis
Unadjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Age <50 years 0.55 0.24 - 1.26 0.16
Female 0.47 0.22 - 1 0.05 0.48 0.22 - 1.03 0.06
Employed 0.43 0.12 - 1.49 0.18
Unemployed 0.77 0.34 - 1.77 0.54
Government support grant 1.44 0.67 - 3.13 0.35
Atrial fibrillation/flutter 2.24 1.05 - 4.78 0.04 2.21 1.02 - 4.77 0.04
Mechanical valve replacement 0.63 0.24 - 1.62 0.34
VTE 0.47 0.18 - 1.21 0.12
APS 0.92 0.1 - 8.14 0.94
Hospital admission 0.4 0.15 - 0.99 0.05 0.4 0.15 - 1.03 0.06
TTR = time in therapeutic range; OR = odds ratio; CI = confidence interval; VTE = venous thromboembolism; APS = antiphospholipid syndrome.
*Demographic and clinical variables that were considered for the regression analysis included age <50 years, female gender, employment status, government support grant, atrial fibrillation/
flutter, mechanical valve replacement, VTE, APS, and hospital admission during the study period. Variables that were significantly associated with a TTR ≥65% (p<0.05) were retained in the 
multivariable model.
Table 5. Association between TTR and total INR tests, INR testing frequency and repeat testing for out-of-range values and TTR
r² p-value
Total number of INR tests during study period 0.01 0.16
Time between INR tests (days) 0.04 0.01
Percentage of out-of-range tests followed up within 7 days with repeat test 0.02 0.08
TTR = time in therapeutic range; INR = international normalised ratio; r² = square of the Spearman rho value.
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with Irbesartan for prevention of Vascular Events (ACTIVE W), all 
demonstrated mean TTRs <60% for patients in the SA cohorts. In all 
three trials there was little difference in INR control between SA public 
and private sites.[4,12,13]
The data from studies performed in developed countries, 
metropolitan settings or dedicated INR clinics cannot be assumed 
to apply to non-metropolitan or rural settings where dedicated 
INR clinics are lacking and a unique set of challenges exist. Many 
patients in rural settings live more remotely from PHCs than their 
counterparts in metropolitan areas, and readily available transport 
to and from clinics is not guaranteed. Public infrastructure, such 
as roads, and public transport in many of these areas in SA are less 
well developed, posing a further challenge to regular easy access to 
healthcare, particularly for ill and frail patients who require care 
most. Many rural areas are serviced by satellite or mobile clinics 
for their health needs on an interval basis only. Community service 
medical officers and nurses play a vital role in staffing the rural and 
remote health facilities across SA. These staff members are required 
to practise in more remote areas with less clinical experience and 
supervision, and regular turnover of staff is commonplace.[17] Access 
to laboratory services and INR testing is a further challenge in 
rural areas. Samples need to be transported to distant laboratories, 
exposing the samples to degradation, and results are not always 
timeously available. Patients may need to return for results on 
different days in order for adjustments to be made to warfarin 
dosages. Cellphone and internet signal is not always available in rural 
areas for telephonic dose adjustments to be facilitated. These factors 
make our findings particularly relevant in the broader SA context. 
The vast majority of South Africans are dependent on government 
facilities for their healthcare. Furthermore, the healthcare needs of 
the majority of South Africans are serviced by PHCs, many of which 
are under-resourced, under-staffed and located far from the nearest 
regional or tertiary facility.[18]
Previous studies have looked at the association between various 
demographic and clinical factors and TTR. Factors found to be 
associated with poor INR control included younger age, patients 
from poorer communities, alcohol abuse, smoking and substance 
abuse.[19] Concurrent medication use, medical comorbidities (cancer, 
chronic liver or kidney disease) and increased hospitalisation were 
also associated with poor INR control, with increased hospitalisation 
in this context being an indirect measure of sicker patients with more 
drug interactions and comorbidities as opposed to an outcome variable 
related to poor INR control.[19,20] Our study confirms the finding of 
worse INR control in younger patients and patients hospitalised for 
any reason during the study period.
In our study, only 22.2% of out-of-range tests were followed up 
with a repeat test within 7 days. There is limited evidence guiding 
the optimal frequency of INR testing. The frequency of testing is 
influenced by the stability of the INR over time, the INR response 
to dose adjustment, and whether a patient is admitted or managed 
as an outpatient.[21] After initiation of therapy or dose adjustments 
as an outpatient, the American College of Chest Physicians (ACCP) 
recommends more frequent INR testing until the INR is stable and 
then at least every 4 weeks.[22] The ACCP furthermore recommends a 
monitoring frequency of up to once every 12 weeks in patients with 
stable INRs who have required no dose adjustments for a period 
of 3  months.[16] It has been shown that shorter intervals between 
INR tests are associated with better INR control.[22] In our study, no 
association could be shown between more frequent INR testing and 
TTR. A larger sample size would be required to further investigate the 
association between the frequency of INR testing and TTR, as well as 
clinical outcomes.
Standardised protocols recommending algorithm-based dosage 
adjustments of warfarin therapy, instead of adjustments based on 
clinical experience, have been associated with improvements in 
TTR. [13,23] Algorithm-based computer programs recommending dose 
adjustments and scheduling follow-up testing have also been shown 
to improve TTR.[24,25] In the Garden Route District Municipality, 
standardised algorithms and protocols are not used to guide decision-
making regarding warfarin therapy, and dose adjustments are made 
at the discretion of the treating clinician.
Self-testing and self-monitoring of the INR in appropriately selected 
patients using PoC devices has been associated with improved patient 
satisfaction and TTR, and a reduction in clinical thromboembolic 
events with no increase in adverse events.[16,26-28] PoC testing is an 
appealing alternative to the routine laboratory measurement of the 
INR, particularly in rural resource-limited settings. In settings similar 
to the Garden Route District Municipality, specimens often need to be 
transported long distances for analysis. Furthermore, patients often 
need to come back to the facility on a different day to get their INR 
result for dosage adjustments to be made. A number of PoC devices 
are on the market. There have been concerns about the reliability of 
PoC INR results across different devices and compared with laboratory 
measurements. However, PoC testing is accepted as a reliable option 
for INR monitoring, with specific advantages over routine laboratory 
testing.[29] It is important to note that PoC INR values that are out of 
range, particularly above range, do become discrepant from laboratory 
values and need confirmation with laboratory testing.[30] PoC testing 
may play an important role in improving the effectiveness of warfarin 
therapy in SA.
Finally, a number of non-vitamin K oral anticoagulants (NOACs) 
are available in SA (rivaroxaban, dabigatran, apixaban). As a class, 
these agents have been shown to be non-inferior or superior to 
warfarin therapy in patients with non-valvular atrial fibrillation, with 
significantly better safety profiles, and are the preferred agents for 
the treatment of VTE.[31-34] Patients with valve lesions were excluded 
from these pivotal trials. The advantages of the use of these agents 
instead of warfarin include a much quicker onset of therapeutic 
levels of anticoagulation, a fixed drug dose with predictable levels 
of anticoagulation, fewer food and drug interactions, and absence 
of the need for regular monitoring of the INR. These agents should 
not be used in patients with prosthetic heart valves or valvular atrial 
fibrillation, or in pregnant patients, and caution needs to be exercised 
in patients with renal failure.[34,35]
Study strengths and limitations
Our study has several limitations. It was a retrospective observational 
study, and limited conclusions can be drawn regarding cause and 
effect. Many variables known to influence warfarin therapy and 
TTR were not analysed, including co-administration of medications, 
alcohol and drug use, smoking, dietary factors and comorbidities. 
The sample size was small, and bigger studies are needed to confirm 
the findings. Although the clinics were selected to represent patients 
from varying demographic settings in the Garden Route District 
Municipality, the findings are not generalisable throughout the 
diverse society of SA. Patient compliance with therapy was not 
accounted for in the study. The contribution of patients defaulting 
follow-up and not taking their treatment undoubtedly plays a role 
in the quality of INR control. Outcomes of INR control were not 
assessed.
The method used to assess the quality of anticoagulation has 
limitations. Because of the assumption of a linear increase or decrease 
in INR between consecutive tests in the Rosendaal method, large time 
gaps between tests (>60 days) can give an incorrect representation of 
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the TTR. However, the percentage of tests in range was also assessed 
and is not influenced by this assumption. Although care was taken 
to exclude patients having INRs tested at different facilities, patients 
moving around between different clinics and districts or between 
the private and public sectors for INR monitoring could not be fully 
accounted for. Whether patients were already established on warfarin 
therapy or newly initiated was not taken into account. Newly initiated 
patients will require time for the INR to stabilise in the therapeutic 
range.
Conclusions
This study is the first to give insight into the current status of warfarin 
therapy in a non-metropolitan PHC setting in SA, which included 
rural clinics. We showed that the quality of INR control in this setting 
is poor and that very few patients are likely to derive any benefit from 
warfarin therapy, with younger and hospitalised patients having the 
highest likelihood of poor INR control. Despite the unique challenges 
regarding anticoagulation therapy in rural areas, there are clear 
gaps in warfarin management that can be addressed by instituting 
basic interventions. The adoption of dose adjustment protocols and 
training of staff in their use may improve INR control. Investment in 
computer-based algorithms and required infrastructure could also 
be beneficial, with the cost weighed against the cost of poor INR 
control. PoC testing will improve the turnaround time of INR tests 
and negate the need for patients to return to PHCs on different days, 
and will further avoid the need for telephonic dose adjustments. On 
a societal level, access to healthcare can be improved by ensuring 
adequate roads, public transport and infrastructure in rural areas. 
The expanded use of NOACs may prove to be uniquely beneficial 
in settings where challenges with INR testing abound that were not 
accounted for in the non-inferiority trials comparing these agents 
with warfarin. While the cost of NOACs, compared with effective 
warfarin therapy, is seen as prohibitive for their expanded use, the 
cost of ineffective warfarin therapy is largely unaccounted for. At the 
very least, increasing the availability of NOACs in the public sector 
for selected patients (e.g. those with non-valvular atrial fibrillation/
flutter and VTE) in whom INR control is proving to be a problem 
despite good adherence, needs to be considered.
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